MN/CAⅨ在肾细胞癌诊断中的价值

Value of MN/CAIX in the diagnosis of renal cell carcinoma

目的探讨MN/CAⅨ在肾细胞癌组织和血液中的表达情况和诊断价值。方法采用RT-PCR技术检测62例肾细胞癌患者肿瘤组织和外周血液中MN/CA IX mRNA的表达,以32例正常肾组织和非肾癌患者外周血作为对照。采用免疫组化技术检测36例肾透明细胞癌,17例其它肾肿瘤,16例正常肾组织标本。结果 RT-PCR结果显示62例肾细胞癌患者MN/CAⅨmRNA阳性率在癌组织中为82.3%(51/62),在外周血中为54.8%(34/62),显著高于对照组(P<0.05),在肾透明细胞癌患者癌组织和外周血中MN/CAⅨmRNA阳性率分别为98%(49/50)和66%(33/50),显著高于其它类型肾癌结果(P<0.05)。免疫组化结果显示MN/CAⅨ在肾透明细胞癌中表达阳性率为97.2%(35/36),明显高于其它类型肾肿瘤和正常肾组织(P<0.05)。结论 MN/CAⅨ在肾细胞癌尤其是透明细胞癌中有特异性的高表达,可以用于肾癌的诊断,尤其在预后和个体化治疗判断上有潜在价值。

Objective To investigate the expression of MN/CAIX in patients with renal cell carcinoma（RCC） and assess the value of MN/CAIX in the diagnosis of RCC.Methods RT-PCR was employed to detect MN/CAIX mRNA in the carcinoma tissue and peripheral blood of 62 patients with RCC,using normal renal tissue and peripheral blood sample from 32 patients without RCC as control.Immunohistochemistry was used to detect MN/CAIX protein in the tissue specimens of clear cell RCC（n=36）,non-clear cell renal neoplasm（n=17） and normal kidney（n=16）.Results The positivity rate of MN/CAIX mRNA was 82.3%（51/62） in renal carcinoma tissues and 54.8%（34/62） in the peripheral blood from patients with RCC,significantly higher than the rates in the control cases（P0.05）.In cases of clear cell renal cell carcinoma,the positivity rate of MN/CAIX mRNA was 98%（49/50） in the carcinoma tissues and 66%（33/50） in the peripheral blood,significantly higher than the rates in cases of non-clear cell type of RCC（P0.05）.Immunohistochemistry showed a significantly higher positivity rate of MN/CAIX protein in clear cell RCC tissues [97.2%（35/36）] than in non-clear cell renal neoplasm and normal renal tissues（P0.05）.Conclusion MN/CAIX is specifically overexpressed in RCC,especially in clear cell RCC,suggesting its potential in the diagnosis and prognostic and therapeutic evaluation of RCC.